

Synthesis of 15R-PGD₂: a potential DP₂ receptor agonist

Seongjin Kim,^a Sophie Bellone,^a Kirk M. Maxey,^b William S. Powell,^c
Gue-Jae Lee^a and Joshua Rokach^{a,*}

^a*Claude Pepper Institute and Department of Chemistry, Florida Institute of Technology, 150 W. University Blvd., Melbourne, FL 32901, USA*

^b*Cayman Chemical, 1180 E. Ellsworth Road, Ann Arbor, MI 48108, USA*

^c*Meakins-Christie Laboratories, Department of Medicine, McGill University, Montreal, Quebec, Canada H2X 2P2*

Received 10 January 2005; revised 3 February 2005; accepted 4 February 2005

Abstract—The first total synthesis of 15R-PGD₂ **3** was accomplished. The approach used in this report is also an efficient method to produce 15R-PGE₂. 15R-PGD₂, a potential DP₂ receptor agonist, could be an important novel tool for defining the role of this receptor in inflammatory diseases.


© 2005 Published by Elsevier Ltd.

Prostaglandin D₂ (PGD₂) **1**,^{1–6} an arachidonic acid metabolite, is produced in mast cells,⁷ dendritic cells,⁸ Th₂ cells,⁹ and in the central nervous system.¹⁰

A large amount of this natural product is released in the lung during asthma and mastocytosis,^{11,12} suggesting that PGD₂ may play a role in these two diseases. We have also proposed that 5-oxo-ETE, a potent chemoattractant for neutrophils¹³ and eosinophils,¹⁴ can be a causative factor in asthma.^{15,16} Until recently, PGD₂ was known to act by raising intracellular cAMP levels through its action on a single G_s-protein-coupled receptor termed the DP₁ receptor.¹⁷ This increase in cAMP levels results in a strong inhibitory effect on platelet aggregation¹⁸ as well as bronchodilator¹⁹ and vasodilator²⁰ effects in humans. However, our group²¹ and other researchers²² independently discovered a second G_i-protein-coupled receptor for PGD₂, which we termed the DP₂ receptor, and which is responsible for the chemo-

attractant effect of PGD₂ on eosinophils and other white blood cells.^{21,22} We have shown²¹ that these cells possess both inhibitory DP₁ receptors and stimulatory DP₂ receptors. The balance between these two receptors is likely to regulate the response of eosinophils and basophils to PGD₂. We recently found that 15R-Me-PGD₂ **2** is a potent and selective agonist for the DP₂ receptor, being about 5 times more potent than PGD₂ and 75 times more potent than 15S-Me-PGD₂ in stimulating actin polymerization, chemotaxis, and expression of the adhesion molecule CD11b²³ (Table 1). Of particular interest is the fact that the stereochemistry of the 15-hydroxy group in **2** is opposite to that in PGD₂ (15S-OH). In contrast to PGD₂, **2** shows no activity on the DP₁ receptor.²³ It could therefore be an important novel tool for defining the physiological role of the DP₂ receptor in asthma, mastocytosis, etc.

The high potency of the 15R-Me-PGD₂ analog **2** raises the possibility that inversion of the configuration at



Keywords: Prostaglandin D₂; 15R-PGD₂; 15R-PGE₂; DP₂ receptor; Eosinophils.

* Corresponding author. Tel.: +1 321 674 7329; fax: +1 321 674 7743; e-mail: jrokach@fit.edu

Table 1. Effects of 15-methyl analogs of PGD₂ on DP₂ mediated responses (EC₅₀, nM) in eosinophils and DP₁, mediated cAMP formation (EC₁₀, nM) in platelets

Compound	DP ₂			DP ₁ cAMP
	CD11b	Actin	Chemotaxis	
PGD ₂	7	13	10	11
15R-Me-PGD ₂	1.4	3.8	1.7	>10,000
15S-Me-PGD ₂	99	333	128	2100


carbon 15 of PGD₂ itself may result in enhanced DP₂ receptor activity. To this end we decided to undertake the total synthesis of 15R-PGD₂ (**3**). The synthesis of **3** was performed in 11 steps as described in Scheme 1. This approach to 15R-PGD₂ is also an efficient method to synthesize 15R-PGE₂ **20**.

One general comment on the synthetic design is warranted. From the outset we decided that the generation of the 11-oxo group of 15R-PGD₂ would be performed at the last step of the synthesis. The facile elimination of the β-hydroxy group in PGE₂ and PGD₂ and related derivatives and analogs is well known.^{24,25} In addition, we also elected not to use a protected carbonyl group, as the deprotection step could be too harsh. We did not want to find this out at the end of the synthesis.


The commercially available lactone benzoate aldehyde **4**²⁶ was our starting point. The Horner–Emmons reaction of **4** with the phosphonate **5**, using lithium hexa-

methyldisilyl amide (LiHMDS) or sodium hexamethyldisilyl amide (NaHMDS) as a base, produced **6** in 80% and 96% yield, respectively. Depending on the base used, different byproducts are formed as shown in Scheme 2.

In the case of NaHMDS, the eliminated compound **21** is obtained in variable amounts (1–10%), whereas with LiHMDS, the *Z*-isomer **22** is obtained in 20% yield. Given the difficulty to separate the *Z*-isomer **22** from the *E*-isomer **6**, the use of the NaHMDS base was preferred. The yield of these byproducts can be reduced from 20% to 5% in the case of **22** and to 1% in the case of **21** by maintaining the reaction at −78 °C for 3 h. Reduction of enone **6** with (*S*)-BINAL-H gave the expected *S*-isomer in >95% ee. Unfortunately the reduction of **6** with (*R*)-BINAL-H was not stereoselective and afforded a mixture of 15-*S* and 15-*R*. This was surprising considering that we have performed (*R*)-BINAL-H reduction in the isoprostane series with excellent stereocontrol.²⁷ A check of the literature reveals that similar compounds to **6** on reaction with (*R*)-BINAL-H also did not show much selectivity for the *R*-isomer.²⁸ Other reducing agents and other C11–OH protecting groups have also been reported.²⁹ We elected to carry the reduction of enone **6** with sodium borohydride, which gave a mixture of the *S*- and *R*-isomers, **7** and **8**. Flash column chromatography afforded the *S*- and *R*-isomer in 45% and 40%, respectively. The structural assignment of **7** and **8** was accomplished as shown in Scheme 3.



Scheme 1. Reagents and conditions: (a) NaHMDS, THF, −78 °C to rt, 96%; (b) NaBH₄, CeCl₃·7H₂O, EtOH, 0 °C to rt, 45% **7**, 40% **8**; (c) TBDMSCl, imidazole, THF, 60 °C, 83%; (d) K₂CO₃, MeOH, rt, 96%; (e) TESCl, pyridine, 60 °C, 98%; (f) DIBAL-H, CH₂Cl₂, −78 °C, 99%; (g) Dess Martin, CH₂Cl₂, rt; (h) (i) *t*-BuOK, HMPA, THF, 0 °C to rt, (ii) CH₂N₂, 62%; (i) DDQ, H₂O, and THF, 0 °C to rt, 82%; (j) 5% KOH, THF, rt, 75%; (k) K₂CO₃, MeOH, rt, 48 h, 79%; (l) Dess Martin, CH₂Cl₂, rt, 94%; (m) formic acid/THF/H₂O (6:3:1), 29% 15R-PGD₂, 58% 15R-PGE₂.



Scheme 2. Side products of the Horner–Emmons reaction depending on the base used.

The identity of isomer **7** was derived from the well established relationship between (*S*)-BINAL-H and *S*-stereochemistry of the OH product. To confirm the identity of the isomer **8**, we oxidized each pure isomer separately with the Dess Martin reagent giving the identical enone **6**. Only the *R*-isomer **8** was used for the following steps of the synthesis.

Protection of **8** with the TBDMS group gave the compound **9** in 83% yield. The benzoate protection, too labile in basic conditions, was replaced in two steps by the more stable TES group to give the product **11**. Then reduction of the lactone **11** using DIBAL-H provided the lactol **13** in 99% yield. Some diol **12** was obtained (1–10%), which can be reoxidized into the lactol **13** with the Dess Martin reagent as shown in Scheme 1.

Wittig reaction of **13** with the phosphonium salt **14**, using potassium *tert*-butoxide as a base, produced selectively the *Z*-isomer **15** in 62% yield. Compound **15** was treated with dichlorodicyanobenzoquinone (DDQ), to deprotect the TES group to afford **16**, followed by 5% aqueous potassium hydroxide to hydrolyze the methyl ester and give **17**. Alternatively, compound **15** can be treated with potassium bicarbonate in methanol for 48 h to simultaneously deprotect the 11-hydroxy and the methyl ester to give **17** in 79% yield. This shortcut is the preferred modification we now use.

Oxidation of **17** with the Dess Martin periodinane reagent produced the compounds **18** and **19** in a 65:35 ratio. Although **18** and **19** separate on TLC (methanol/ethylacetate/hexane, 3:65:32), we found the separation by flash column chromatography to be quite tedious and the isolation of the desired 15R-PGD₂ was realized at the final step of the synthesis after deprotecting the mixture **18** and **19** with formic acid. We obtained not only 15R-PGD₂ **3**³⁰ in 29% yield, but also 15R-PGE₂

Table 2. Effect of 15R-PGD₂ on actin polymerization and cAMP


Treatment	Actin polymerization (eosinophils) (% above control)	cAMP (platelets) (pmol)
Vehicle	—	0.05 ± 0.02
15R-PGD ₂ (1 μM)	83.8 ± 7.5	0.83 ± 0.21
PGD ₂ (1 μM)	86.2 ± 4.2	15.48 ± 1.97

20³¹ in 58% yield. The identity of **20** was confirmed by comparison with an authentic sample.

15R-PGD₂ is currently being analyzed for its potential activity on PGD₂ receptors. Preliminary results suggest that its activity at the DP₂ receptor is similar to that of PGD₂, but it has very little activity at the DP₁ receptor. As shown in Table 2, 15R-PGD₂ and PGD₂, using methodology we described recently,²³ induce virtually identical increases in actin polymerization in human eosinophils, which is a DP₂ receptor-mediated response. In contrast, 15R-PGD₂ induces only a very modest increase in cAMP levels in platelets, which is mediated by the DP₁ receptor. The cAMP response elicited by PGD₂ is about 20 times greater than 15R-PGD₂. Thus it would appear that 15R-PGD₂ is highly selective for the DP₂ receptor. Further studies are underway on the biological effects of this compound.

Acknowledgments

We wish to acknowledge the NIH for support under Grants DK-44730 and HL-69835 (J.R.), the NSF for an AMX-360 NMR Instrument Grant CHE-90-13145 (J.R.), and the CIHR of Canada for Grant MOP-6254 (W.S.P.), and Korea Science & Engineering Foundation (KOSEF).



Scheme 3. Identification of the *S*- and *R*-isomers.

References and notes

1. Crabbe, P. In *Organic Chemistry*; Blomquist, A. T., Wasserman, H. H., Eds.; Academic: New York, 1977; Vol. 36, p 442.
2. Hayashi, M.; Tanouchi, T. *J. Org. Chem.* **1973**, *38*, 2115.
3. Nishizawa, E. E.; Miller, W. L.; Gorman, R. R.; Bundy, G. L.; Svensson, J.; Hamberg, H. *Prostaglandins* **1975**, *9*, 109.
4. Jenny, E. F.; Schaublin, P. *Tetrahedron Lett.* **1974**, *26*, 2235.
5. Bindra, J. S.; Bindra, R. *Prostaglandin Synthesis*; Academic: New York, 1977.
6. Nicolaou, K. C.; Petasis, N. A. In *CRC Handbook of Eicosanoids: Prostaglandins and Related Lipids. Chemical and Biochemical Aspects, Part B*; Willis, A. L., Ed.; CRC: Boca Raton, FL, 1987; Vol. I, p 1.
7. Urade, Y.; Ujihara, M.; Horiguchi, Y.; Igarashi, M.; Nagata, A.; Ikai, K.; Hayaisha, O. *J. Biol. Chem.* **1990**, *265*, 371.
8. Urade, Y.; Ujihara, M.; Horiguchi, Y.; Ikai, K.; Hayaisha, O. *J. Immunol.* **1989**, *143*, 2982.
9. Tanaka, K.; Ogawa, K.; Sugamura, K.; Nakamura, M.; Takano, S.; Nagata, K. *J. Immunol.* **2000**, *164*, 2277.
10. Urade, Y.; Hayaisha, O. *Biochim. Biophys. Acta* **2000**, *1482*, 259.
11. Murray, J. J.; Tonnel, A. B.; Brash, A. R.; Roberts, L. J.; Gosset, P.; Workman, R.; Capron, A.; Oates, J. A. *N. Engl. J. Med.* **1986**, *315*, 800.
12. Roberts, L. J.; Sweetman, B. J.; Lewis, R. A.; Austen, K. F.; Oates, J. A. *N. Engl. J. Med.* **1980**, *303*, 1400.
13. Powell, W. S.; Gravel, S.; MacLeod, R. J.; Mills, E.; Hashefi, M. *J. Biol. Chem.* **1993**, *268*, 9280.
14. Powell, W. S.; Chung, D.; Gravel, S. *J. Immunol.* **1995**, *154*, 4123.
15. Khanapure, S. P.; Shi, X. X.; Powell, W. S.; Rokach, J. *J. Org. Chem.* **1998**, *63*, 337.
16. Berhane, K.; Ray, A. A.; Khanapure, S. P.; Rokach, J.; Powell, W. S. *J. Biol. Chem.* **1998**, *273*, 20951.
17. Narumiya, S.; Sugimoto, Y.; Ushikubi, F. *Physiol. Rev.* **1999**, *79*, 1193.
18. Miller, O. V.; Gorman, R. R. *J. Pharmacol. Exp. Ther.* **1979**, *210*, 134.
19. Norel, X.; Walch, L.; Labat, C.; Gascard, J. P.; Dulmet, E.; Brink, C. *Br. J. Pharmacol.* **1999**, *126*, 867.
20. Walch, L.; Labat, C.; Gascard, J. P.; deMontpreville, V.; Brink, C.; Norel, X. *Br. J. Pharmacol.* **1999**, *126*, 859.
21. Monneret, S.; Gravel, S.; Diamond, M.; Rokach, J.; Powell, W. S. *Blood* **2001**, *98*, 1942.
22. Hirai, H.; Tanaka, K.; Yoshie, O.; Ogawa, K.; Kenmotsu, K.; Takamori, Y.; Ichimasa, M.; Sugamura, K.; Nakamura, M.; Takano, S.; Nagata, K. *J. Exp. Med.* **2001**, *193*, 255.
23. Monneret, G.; Cossette, C.; Gravel, S.; Rokach, J.; Powell, W. S. *J. Pharmacol. Exp. Ther.* **2003**, *304*, 349.
24. Crabbe, P.; Cervantes, A.; Meana, C. *J. Chem. Soc., Chem. Commun.* **1973**, 119.
25. Mitra, A. *The Synthesis of Prostaglandins*; Wiley: New York, 1977.
26. Yankee, E. W.; Axen, U.; Bundy, G. L. *J. Am. Chem. Soc.* **1974**, *96*, 5865.
27. Khanapure, S. P.; Manna, S.; Rokach, J.; Murphy, R. C.; Wheelan, P.; Powell, W. S. *J. Org. Chem.* **1995**, *60*, 1806.
28. Noyori, R.; Tomino, I.; Yamada, M.; Nishizawa, M. *J. Am. Chem. Soc.* **1984**, *106*, 6717.
29. Corey, E. J.; Bakshi, R. K.; Shibata, S.; Chen, C.-P.; Singh, V. K. *J. Am. Chem. Soc.* **1987**, *109*, 7925.
30. *The NMR data of the compound 3*: ^1H NMR (360 MHz, CDCl_3), δ 5.6 (m, 2H), 5.45 (m, 2H), 4.55 (m, 1H), 4.18 (q, $J = 13$ and 6.3 Hz, 1H), 2.8 (dd, $J = 12.1$ and 8.5 Hz, 1H), 2.45 (m, 3H), 2.35 (t, $J = 6$ Hz, 2H), 2.15 (m, 3H), 1.95 (m, 1H), 1.65 (m, 4H), 1.3 (m, 6H), 0.9 (t, $J = 6$ Hz, 3H); ^{13}C NMR (360 MHz, CDCl_3), δ 217, 175, 138.5, 131.5, 128, 127.5, 74, 68, 55, 54, 50, 48, 38, 33, 32, 26, 25.5, 25, 23, 14.
31. *The NMR data of the compound 20*: ^1H NMR (360 MHz, CDCl_3), δ 5.72 (dd, $J = 15.4$ and 6.4 Hz, 1H), 5.6 (dd, $J = 15.4$ and 8.3 Hz, 1H), 5.45 (m, 2H), 4.15 (q, $J = 15.3$ and 9 Hz, 2H), 2.75 (dd, $J = 18.5$ and 7.5 Hz, 1H), 2.35 (m, 4H), 2.25 (m, 2H), 2.1 (m, 3H), 1.6 (m, 4H), 1.3 (m, 6H), 0.9 (t, $J = 6$ Hz, 3H).